CICLOPIROX
Clinical safety rating: safe
Animal studies have demonstrated safety
Ciclopirox is a hydroxypyridone antifungal agent that chelates polyvalent metal cations (e.g., Fe3+, Al3+) inhibiting metal-dependent enzymes, thereby disrupting fungal cellular metabolic processes, including mitochondrial electron transport and energy production.
| Metabolism | Minimal systemic absorption following topical application. The small absorbed fraction is primarily metabolized via glucuronidation and oxidation. Unchanged drug and metabolites are excreted renally and fecally. Specific hepatic enzymes involved are not well characterized. |
| Excretion | Renal: approximately 70-80% of the absorbed dose as unchanged drug and glucuronide conjugates; biliary/fecal: ~20-30% |
| Half-life | Terminal elimination half-life: 1.7-3.0 hours in healthy individuals; prolonged in hepatic impairment |
| Protein binding | 94-98% bound to plasma proteins, primarily albumin |
| Volume of Distribution | 1.2-2.0 L/kg, indicating extensive tissue distribution |
| Bioavailability | Topical: minimal systemic absorption (<1-5% of applied dose); oral: not formulated for systemic use |
| Onset of Action | Topical: antifungal effect within 24-48 hours; systemic (oral): not applicable for systemic use |
| Duration of Action | Topical: sustained antifungal activity for up to 48 hours after application; requires twice-daily dosing for most indications |
Ciclopirox 8% nail lacquer: Apply to affected nails once daily for up to 48 weeks. Ciclopirox 1% cream or lotion: Apply to affected skin twice daily for 2-4 weeks. Ciclopirox 1% shampoo: Apply to wet hair, lather, leave for 3 minutes, rinse; use twice weekly for 4 weeks (for seborrheic dermatitis).
| Dosage form | CREAM |
| Renal impairment | No specific dose adjustments are recommended; systemic absorption is minimal (<1.3%) with topical application. For oral use (not available in the US), no data for renal impairment. |
| Liver impairment | No dose adjustments needed for topical use due to negligible systemic absorption. No data for oral formulations. |
| Pediatric use | Ciclopirox 1% cream: Approved for children ≥10 years with tinea pedis or tinea corporis; apply twice daily for 2 weeks. Ciclopirox 8% nail lacquer: Not recommended in children <12 years. Ciclopirox 1% shampoo: Not established in children <16 years. |
| Geriatric use | No specific dose adjustments; topical use has minimal systemic absorption. Consider skin thinning and increased risk of irritation in elderly; use caution with prolonged application. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions For topical use only not for ophthalmic use.
| Breastfeeding | It is unknown if ciclopirox is excreted in human milk. Due to low systemic absorption after topical application, the amount ingested by a nursing infant is likely negligible. Use with caution on small areas and avoid application to breast. M/P ratio not established. |
| Teratogenic Risk | Topical ciclopirox has minimal systemic absorption ( < 1.5%) and is generally considered low risk. Animal studies with high doses have shown fetal toxicity, but no teratogenicity in rats or rabbits. For topical use, there is no evidence of teratogenicity in humans. However, sufficient data are lacking for first trimester risk. The drug should be used during pregnancy only if clearly needed, with caution primarily in first trimester. |
■ FDA Black Box Warning
None currently listed in FDA labeling.
| Common Effects | nail infections |
| Serious Effects |
["Hypersensitivity to ciclopirox or any component of the formulation"]
| Precautions | ["For external use only; avoid contact with eyes and mucous membranes","If irritation or sensitivity develops, discontinue treatment","Not for intravaginal or ophthalmic use","Use in diabetic patients may require additional monitoring for nail infections","Keep away from heat and open flame (ciclopirox solution contains alcohol)"] |
| Food/Dietary | No significant food interactions have been reported with topical ciclopirox. For oral ciclopirox (not available in the US), food may affect absorption; consult prescribing information. |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring is required beyond standard obstetric care. For extensive use, observe for maternal systemic effects (rare). No fetal monitoring indicated. |
| Fertility Effects | Animal studies have not demonstrated impaired fertility at clinically relevant doses. No human data are available but systemic exposure is minimal with topical use; therefore, significant impact on fertility is unlikely. |
| Clinical Pearls | Apply topical ciclopirox once or twice daily, covering the lesion and a 1 cm margin of normal skin. For nail infections, file away loose nail material before applying lacquer. Avoid occlusive dressings unless directed. Treatment duration for tinea pedis is 2 weeks; for tinea corporis/cruris, 2-4 weeks. For onychomycosis, treatment may require 48 weeks or until nail replacement. |
| Patient Advice | Wash hands before and after applying the medication. · Apply a thin layer to the affected area and rub in gently. · Do not use on open wounds, or in eyes, mouth, or vagina. · For nail lacquer, apply daily over the entire nail plate and to the underside of the nail tip. · Avoid nail polish or artificial nails during treatment. · Complete the full course even if symptoms improve. · Notify your doctor if irritation or allergic reaction occurs. |